Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.

Shintaro NaritaTakahiro KimuraShingo HatakeyamaKenichi HataTakafumi YanagisawaShinya MaitaShuji ChibaHiromi SatoSoki KashimaAtsushi KoizumiRyohei YamamotoKoichiro TakayamaKatsumi OkaneToshiya IshidaYohei HorikawaTeruaki KumazawaJiro ShimodaTakehiro SuzukiChikara OhyamaShin EgawaTomonori Habuchi

Published in: International journal of clinical oncology (2022)

Upfront ABI provided better CRPC-free survival than upfront DOC; however, no significant differences in PFS2 or OS were observed between the two groups. Personalized management based on prognostic risk factors may benefit patients with mCSPC treated with upfront intensified therapies.

Keyphrases

free survival
prostate cancer
risk factors
radical prostatectomy
squamous cell carcinoma
newly diagnosed
type diabetes
radiation therapy
metabolic syndrome
adipose tissue
insulin resistance